^
Association details:
| Biomarker: | AKT1 E17K |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | Tecentriq (atezolizumab) (PD-L1 inhibitor) + ipatasertib (RG7440) (PI3K inhibitor, AKT inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
187P - Ipatasertib and atezolizumab in cancers with increased PI3K-AKT pathway activity: First results from the CRAFT trial
Published date:
10/16/2023
Excerpt:
We report the interim efficacy analysis of ipatasertib and atezolizumab in cancers with increased PI3K-AKT pathway activity....One patient with breast cancer and a homozygous AKT1 E17K and one patient with prostate cancer and PTEN loss achieved a PR and SD, respectively.
Trial ID:
